Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fufang Xiolingdan Mixture is a Traditional Chinese Medicine (TCM) compound liquid formulation developed by the Kunming Municipal Hospital of Traditional Chinese Medicine. It is specifically indicated for the treatment of influenza, particularly the 'Wind-Heat Invasion' syndrome (Wind-Heat invading the defensive system) as defined in TCM theory. As a 'Fufang' (compound) preparation, it consists of a synergistic blend of botanical extracts designed to clear heat, resolve toxins, and alleviate systemic symptoms such as fever and respiratory distress. The mixture has been evaluated in randomized, double-blind, placebo-controlled clinical trials in China for its efficacy and safety in adult patients with laboratory-confirmed influenza, with a focus on administration within 48 hours of symptom onset.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fufang Xiolingdan Mixture.